Press Releases

LOS ANGELES, June 11, 2026 /PRNewswire/ -- Southern California Gas Co. (SoCalGas), a subsidiary of Sempra (NYSE:SRE), announced today that its energy efficiency programs helped customers save more than $106 million on their utility bills in 2025—reducing energy use by approximately 54 million net therms, enough to serve about 38,000 homes annually1."These programs are giving customers more control of their energy use and helping lower their bills," Andy Carrasco, vice president, communications and regional stakeholder engagement at SoCalGas. "We're providing simple, practical tools, rebates, and services so families and small businesses across Southern California can save energy and better m

Expanded U.S. availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery. Cataracts are one of the leading causes of vision impairment.1 Nearly 20% of Americans aged 40+ live with cataracts that make everyday tasks more challenging, yet only 5% have had cataract surgery.2 Over half a million eyes worldwide have already experienced clearer, extended range of vision with TECNIS PureSee IOL after cataract surgery.3,4 97% of patients would recommend TECNIS PureSee IOL to friends or family.5 Johnson & Johnson (NYSE:JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs)

Netflix is forecast to reach nearly 400 million subscribers worldwide by the end of 2031, reinforcing its position as the world's leading subscription streaming platform despite growing consolidation across the industry. New forecasts from Omdia presented at NEM Dubrovnik 2026 indicate that scale, profitability and audience reach will increasingly shape the next phase of streaming competition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611055849/en/Top 10 pay TV and online video subscribers (million) 2025-2031 Omdia's forecasts highlighted Netflix's continued expansion despite increasing merger and acquisition activity am

IM-1617 is a potential first-in-class solid tumor antibody-drug conjugate (ADC) that incorporates HC74, Immunome's proprietary topoisomerase I (TOP1) inhibitor payload Immunome ADC pipeline momentum anticipated to continue with investigational new drug (IND) submissions for IM-1340 and IM-1335 planned for mid- and late 2026, respectively Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC directed at an undisclosed solid tumor target and incorporating HC74, Immunome's

NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026. "Yesterday, we were pleased to announce that we reached the completion of the last patient last visit of our pivotal Phase 3 TransportNPC™ trial, and we are grateful for the patients and families, advocacy organizations, and physicians who stood at the heart of this global effort. Together, we have advanced the clinical understanding of NPC, as well as the lived experience of this devastating disease, as we work to deliver a potentially life changing treatment option for a community with significant unmet need,"

AUSTIN, Texas, June 11, 2026 (GLOBE NEWSWIRE) -- Swarmer, Inc. ("Swarmer") (NASDAQ:SWMR), a drone autonomy software company which has supported more than 100,000 real-world combat missions in Ukraine since April 2024, today issued a letter from its Chairman, Erik Prince. Dear Shareholders, I am writing this letter after returning from five days on the ground in Ukraine, where I visited some of the most innovative defense technology companies operating anywhere in the world today. These are not companies building to a specification or a procurement cycle. They are building to survive testing their assumptions daily against real adversaries, iterating in hours rather than years, and produc

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos"), an innovative global cannabinoid company, today announced that its Spinach® vape portfolio has become the top‑selling vape brand in Canada, capturing 10.4%1 market share of the total vapes category in April 2026, a position that Cronos has held since January 2026. Since entering the vape category, the Spinach® brand has built a best‑in‑class offering rooted in quality, flavor, and technology. Spinach® vapes are crafted using high‑purity extracts, feature vibrant and distinctive terpene profiles, and utilize advanced hardware designed to deliver smooth, reliable performance for adult consumers

NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced that Amir Inamdar, Helus Pharma's Chief Medical Officer, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference taking place June 15-16, 2026. The fireside chat will be available on demand beginning on Monday, June 15 at 7:00 a.m. EDT. To register for the webcast, click here. A replay will be available on the Events & Presentations page of Helus Pharma's investor relations website. About Helus Phar

Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone  Topline data readout, including primary endpoint of overall survival, anticipated in mid-2028 NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that the first patient has been dosed in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer patien

PHILADELPHIA, June 11, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced submission of an Investigational New Drug (IND) application to the Department of Health, Abu Dhabi (DOH) for PRECISION-E2, a first-of-its-kind, Phase 2a genomics-enabled clinical trial evaluating Teverelix® in women with symptomatic endometriosis in the United Arab Emirates (UAE). The PRECISION-E2 study is designed to combine clinical outcomes, hormonal biomarkers, pharmacokinetic and pharmacodynamic measurements, and geno

New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life Follow-up data show substantial reductions in phlebotomy use persisting after final dose Phase 2 SANRECO study evaluating Q6W and Q12W dosing remains on-track for topline results in August 2026 Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6, in 21 phlebotomy-dependent patients with polycythemia vera (PV) at the European Hematolo

WEST PALM BEACH, Florida, June 11, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced plans to establish an Advanced Filament Manufacturing Division within its Connecticut defense technology manufacturing complex, in connection with the Company's previously announced plans to acquire a U.S.-based manufacturing facility. The division is designed to supply proprietary 3D-printing materials to the Company's planned 80-3D Printer drone production farm and to serve as

Fiscal Year 2027 Positioned for Revenue Growth and Accelerating Profitability McGraw Hill, Inc. (NYSE:MH) ("McGraw Hill" or the "Company"), a leading global provider of education solutions for preK-12, higher education and professional learning, today announced financial results for the fiscal fourth quarter 2026 and year-end March 31, 2026. Key Fiscal Year 2026 Financial Highlights Total revenue of $2,102.8 million, an increase of 0.1% year-over-year, driven by strong Higher Education execution, offsetting the anticipated smaller K-12 market opportunity driven by procurement cycles. Re-occurring revenue of $1,541.0 million, an increase of 5.8% year-over-year, representing more th

As a pilot participant, Infosys contributed to shaping the CMMI AI Maturity (AIM) framework – bringing enterprise-scale AI practices, governance models, and real-world deployment insights – powered by Infosys Topaz AI offerings – to define industry benchmarksAmong the first organizations globally to complete the CMMI AI Maturity Pilot AssessmentBENGALURU, India, June 11, 2026 /CNW/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE:INFY), a global leader in AI-first business consulting and technology services, today announced that it has successfully completed and contributed to the CMMI AI Maturity (AIM) Framework and Pilot Assessment, conducted by CMMI® Institute, a global leader in helping organiza

Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk features New European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor.

BERLIN, June 11, 2026 /PRNewswire/ -- Travelzoo® (NASDAQ:TZOO), the club for travel enthusiasts, announces four of many new Club Offers for Club Members in Germany. Rigorously vetted and negotiated for us travel enthusiasts:FROM €1399—7 NIGHTS IN CROATIA FOR 6 PEOPLE A private community of 15 villas in Istria. Every house has at least three bedrooms and a private pool. Beaches and coastal towns are right on your doorstep. We're saving 62% compared to booking directly with the hotel.FROM €549 PP—ISTANBUL WITH FLIGHTS & PRIVATE DRIVER This 3-night stay is in a centrally located luxury hotel. Flights, breakfast, and airport transf

LAKEWOOD, Colo., June 11, 2026 /PRNewswire/ -- Natural Grocers®, the leading family-operated organic and natural grocery retailer in the U.S., invites customers to its annual New Mexico Day event, June 14 through June 16 at its seven New Mexico stores. {N}power® members are invited to celebrate with a free Natural Grocers reusable tote bag and a $5-off coupon for in-store purchases. NATURAL GROCERS – NEW MEXICOHeadquartered in Colorado, Natural Grocers expanded into New Mexico in 2003. Today Natural Grocers operates seven stores in the Land of Enchantment, including Albuquerque, Farmington, Las Cruces, Los Alamos, Rio Rancho, R

--Revenue increases 8% to $484 million with same store sales growth of 2%-- --Take 5 same store sales increase 4.5%; 23rd consecutive quarter of growth-- --Net leverage ratio improves to 3.2x Adjusted EBITDA-- --Company reiterates fiscal year 2026 outlook-- Driven Brands Holdings Inc. (NASDAQ:DRVN) ("Driven Brands" or the "Company") today reported financial results for the first quarter ending March 28, 2026. For the first quarter, Driven Brands delivered revenue of $484.4 million, an increase of 8% versus the prior year. System-wide sales increased 6% to $1.6 billion, driven by a 2% increase in same store sales and 5% increase in store count versus the prior year. Net income fr

TORONTO, June 11, 2026 /PRNewswire/ -- Thomson Reuters (TSX/Nasdaq: TRI) today announced the voting results for the election of the company's Board of Directors at its annual meeting of shareholders held in-person yesterday. All 14 nominees were elected to the Thomson Reuters Board of Directors. Michael Medline and Liz Hilton Segel are newly elected directors. Each director elected will continue to hold office until Thomson Reuters' next annual meeting of shareholders, or until the director resigns or a successor is elected or appointed. The voting results for directors were as follows:Nominee     Votes For             % Votes 

Coursera, Inc. (NYSE:COUR), a leading global online learning platform, today announced that it will host a supplemental post-merger modeling call on Tuesday, June 23, 2026, at 5:30 a.m. PT / 8:30 a.m. ET. The company's chief financial officer, Mike Foley, will provide an overview of the combined company's full year 2026 financial profile following the close of its merger with Udemy on May 11, 2026. Prepared remarks will be followed by an analyst question-and-answer session.A live webcast and archived replay of the virtual conversation will be available on Coursera's investor relations website at investor.coursera.com.Disclosure InformationIn compliance with disclosure obligations under Regul